Product Details
Product Name:
Tecadenoson |
CAS No.:
204512-90-3 |
Purity:
99.76% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | Tecadenoson |
Description | Tecadenoson (CVT-510) is a selective A1 adenosine receptor agonist. |
In vitro | Tecadenoson is approximately 5 fold more potent to prolong the stimulus-to-His bundle (S-H interval), a measure of slowing AV nodal conduction (EC50=41?nM) than to increase coronary conductance (EC50=200?nM) in the atrial-paced isolated heart. Tecadenoson shortens atrial (EC50=73?nM) but not the ventricular monophasic action potentials (MAP). At concentrations of Tecadenoson (40?nM) and diltiazem (1?μM) that induces equal prolongation of S-H interval (~10?ms), diltiazem, but not Tecadenoson, significantly decreases left ventricular developed pressure (LVP) and markedly increases coronary conductance [1]. |
In vivo | Intravenous infusions of Tecadenoson and diltiazem causes nearly equal prolongations of P-R interval In atrial-paced anaesthetized guinea-pigs. Tecadenoson (2, 5, 20 μg/kg i.p.) causes a rapid and sustained dose-dependent decrease in NEFA at doses that do not cause bradycardia. Tecadenoson (50 μg/kg) treatment induces a significant bradycardia (50% decrease in heart rate at 25 min) [1][2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 155 mg/mL (459.49 mM)
|
Keywords | Inhibitor | CVT 510 | P1 receptor | Adenosine Receptor | CVT510 | inhibit | Tecadenoson |
Inhibitors Related | Theophylline monohydrate | Diphylline | Acefylline | Nitrobenzylthioinosine | Aminophylline | Inosine | Theobromine | Istradefylline | Theophylline | Adenosine antagonist-1 | Doxofylline | FK-453 |
Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library | Nucleotide Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:36531-78-9
$1960.00 / 2500μg
-
CAS:6064-63-7
$30.00 / 100mg
-
CAS:56-10-0
$38.00 / 500mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |